Kingworld Medicines Group Limited

1110

KYG5268M1006

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 09:08:12 17/06/2024 BST			5-day change	1st Jan Change
0.58 ^HKD	+1.75%		-1.69%	-7.94%

05-29	Kingworld Medicines Group Limited Approves Final Dividend for the Year Ended 31 December 2023	CI
04-23	Kingworld Medicines Posts 68% Jump in 2023 Profit	MT

Kingworld Medicines Group Limited Announces Change of Address of Principal Place of Business in Hong Kong, Effect from 23 September 2021

September 20, 2021 at 02:00 pm

Kingworld Medicines Group Limited announced that with effect from 23 September 2021, the address of principal place of business of the Company in Hong Kong will be changed from Room 1906-1907, 19th Floor, Shui On Centre, 6-8 Harbour Road, Wanchai, Hong Kong to Unit 613, 6th Floor, Goodluck Industrial Centre, 808 Lai Chi Kok Road, Kowloon, Hong Kong.

Latest news about Kingworld Medicines Group Limited

Kingworld Medicines Group Limited Approves Final Dividend for the Year Ended 31 December 2023	05-29	CI
Kingworld Medicines Posts 68% Jump in 2023 Profit	04-23	MT
Kingworld Medicines Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 28 June 2024	03-27	CI
Kingworld Medicines Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Kingworld Medicine Expects Up to 75% Profit Jump in 2023; Shares Up 6%	03-21	MT
Kingworld Medicines Group Limited Provides consolidated Earnings Guidance for the Year Ended 31 December 2023	03-20	CI
Kingworld Medicines Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23	CI
Kingworld Medicines Subsidiary Buys Shares in Taiko Pharmaceutical	16/08/23	MT
Kingworld Medicines Group Expects Up to 40% Rise in H1 Profit	03/08/23	MT
Kingworld Medicines Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2023	02/08/23	CI
Kingworld Medicines Group Limited Approves Final Dividend for the Year Ended 31 December 2022	29/05/23	CI
Kingworld Medicines to Invest 832 Million Yen in Taiko Pharmaceutical	25/04/23	MT
Kingworld Medicines to Grant 3.5 Million Awarded Shares Under 2019 Scheme	07/04/23	MT
Kingworld Medicines Group Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2022, Payable on 30 June 2023	30/03/23	CI
Kingworld Medicines Group Limited Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
KIngworld Medicines Group Acquires 60% Stake in Innopharm	17/10/22	MT
Kingworld Medicines Completes Topping Out Process of Longde Health Industrial Park	10/10/22	MT
Kingworld's H1 Profit Jumps	14/09/22	MT
Kingworld Medicines Group Limited Reports Earnings Results for the Half Year Ended June 30, 2022	31/08/22	CI
Kingworld Medicines Group Forecasts Up To 25% Rise in H1 Net Profit	11/08/22	MT
Kingworld Medicines Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2022	10/08/22	CI
Kingworld Medicines Group Limited Announces Final Cash Dividend for the Financial Year Ended 31 December 2021, Payable on 30 June 2022	27/05/22	CI
Kingworld Medicines Group Limited Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 30 June 2022	29/03/22	CI
Kingworld Medicines Group Limited Reports Earnings Results for the Full Year Ended December 31, 2021	29/03/22	CI
Kingworld Medicines Sees up to 160% Surge in 2021 Profit	23/03/22	MT

Chart Kingworld Medicines Group Limited

Duration

Period

More charts

Company Profile

Kingworld Medicines Group Limited is an investment holding company principally engaged in the distribution and sales of pharmaceutical and healthcare products. The Companyâs products include cough and phlegm relieving, gastrointestinal, vitamin, orthopedics, cardiovascular, influenza and others. The Company operates through two business segments. The Distribution Sales of Pharmaceutical and Healthcare Products segment is engaged in the distribution and sales of branded imported pharmaceutical and healthcare products primarily in Hong Kong and the Peopleâs Republic of China (PRC). The Manufacturing and Sales of Electrotherapeutic and Physiotherapeutic Devices and General Medical Examination Devices segment is engaged in the manufacture and sales of electrotherapeutic and physiotherapeutic devices, as well as general medical examination devices in the PRC.

Sector

Pharmaceuticals

Calendar

25/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
KINGWORLD MEDICINES GROUP LIMITED	-7.94%	43.23M
MCKESSON CORPORATION	+27.96%	76.68B
CARDINAL HEALTH, INC.	-1.41%	24.41B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+10.46%	8.48B
HUADONG MEDICINE CO., LTD	-25.33%	7.47B
H. LUNDBECK A/S	+13.92%	5.21B
GALENICA AG	0.00%	4.12B
EBOS GROUP LIMITED	-8.45%	3.86B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	-3.20%	3.56B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+14.22%	3.4B

Pharmaceuticals Wholesale